December 9, 2014 / 2:18 PM / 3 years ago

BUZZ-U.S. Stocks on the Move-Conn's, Autozone, Bluebird Bio, Idera

7 Min Read

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)

U.S. stock index futures declined on Tuesday, putting the S&P 500 on track to extend losses after suffering its biggest drop since Oct. 22 in the prior session on concerns about global growth. Dow Jones industrial average futures were down 0.81 percent at 17,706, S&P 500 futures were down 0.89 percent at 2,041.25 and Nasdaq 100 futures were down 0.93 percent at 4,239.

** CONN'S INC, Monday close $35.09, -35.88 pct premarket

The electronics and home appliance retailer withdrew its 2015 profit forecast. CFO Brian Taylor resigned and Mark Haley was appointed interim CFO. The company reported a third-quarter loss of 8 cents per share, compared with a profit of 66 cents per share a year earlier. Conn's, which has been exploring strategic alternatives, said it is "actively engaged" in preliminary discussions with multiple parties.

** AUTOZONE INC, Monday close $581.05, +3.78 pct premarket

The second-largest U.S. auto parts retailer reported a higher-than-expected quarterly profit, helped by lower gas prices and colder-than-usual weather that encouraged customers to ready their cars for a harsh winter.

** BHP BILLITON LTD, Monday close $49.05, -2.18 pct premarket

The miner's U.S. and Australia-listed shares fell after Brent crude oil hit a fresh 5-year low of $65.29/bbl on Tuesday before rebounding to $67/bbl.

** BLUEBIRD BIO INC, Monday close $48.89, +56.84 pct premarket

The drug developer said four beta-thalassemia patients transplanted with its LentiGlobin product, including one with the most severe form of the genetic blood disorder, were essentially cured, prompting several brokerages to raise their price targets on the stock. Roth Capital Partners raised its price target to $90 from $50, Piper Jaffray to $112 from $52, Suntrust Robinson to $115 from $57 and Wedbush Securities to $94 from $51

** IDERA PHARMACEUTICALS INC, Monday close $4.41, +1.36 pct premarket

The drug developer showed positive pre-clinical, early- and mid- stage data from different studies of its experimental blood cancer drug at the American Society of Hematology (ASH). Data presented from one study supported development of its lead compound, IMO-8400, in combination with cancer drug rituximab.

** UTI WORLDWIDE INC, Monday close $13, -9.38 pct premarket

The logistics company said Chief Executive Eric Kirchner had resigned and Edward Feitzinger would replace him, effective immediately. Feitzinger, who joined UTi in 2010, had been executive vice president of global operations since 2012.

** ABBVIE INC, Monday close $69.42

Indian drugmaker Cadila Healthcare Ltd said it launched the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its U.S. price. The drug's branded version is sold under the name Humira by U.S. firm AbbVie Inc, and costs $1,000 for a vial in the United States.

** SEADRILL LTD, Monday close $11.57, +1.99 pct premarket

The Norway-based driller's stock rose following a share purchase by chairman & top owner, billionaire investor John Fredriksen, who raised his stake to 24.15 percent on Tuesday, buying 1.3 million more shares at $11.68 per share, a day after his investment vehicle Hemen Holding bought 2.7 million shares on Monday.

** MAZOR ROBOTICS LTD, Monday close $12.12, +9.74 pct premarket

The Israel-based medical device-maker said it received two orders in China and one in Taiwan for its Renaissance surgery guidance systems. The orders from China are the company's first since the China Food and Drug Administration approved the system.

** VERIZON COMMUNICATIONS INC, Monday close $48.9, -3.15 pct premarket

The largest U.S. wireless carrier said promotional offers and price cuts in its wireless business would eat into profit for the fourth quarter.

** SONY CORP, Monday close $21.15, -2.36 pct premarket

Sony Pictures Entertainment was demanded by a group that claimed responsibility for the massive computer hack at the company to cancel the release of "The Interview," a film comedy that depicts an assassination plot against North Korea's leader.

** VALEANT PHARMACEUTICALS INTERNATIONAL INC, Monday close $143.94

The Canadian drugmaker is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position.

** AMAZON.COM INC, Monday close $306.64, -1.25 pct premarket

The U.S. online retailer Amazon.com Inc plans to shift more of its drone testing outside U.S. borders unless it gets quick permission from U.S. regulators to conduct outdoor trials.

** WHITING PETROLEUM CORP, Monday close $32.27, -0.28 pct premarket

The oil and gas producer's buyout of Kodiak Oil and Gas Inc is worth $1.55 billion based on Monday's closing stock price, about $2.25 billion less than when first announced last July.

** CHEVRON CORP, Monday close $106.8, -0.15 pct premarket

Chevron is partnering with Norway's Statoil to explore three prospects off the lightly explored south-east coast of New Zealand's North Island. Statoil is already in New Zealand and has been awarded a further offshore block in its own right at the top northwest coast of the North Island.

** PETROBRAS SA, Monday close $8.75

The Brazilian state-run oil company faces a lawsuit in a federal court in New York related to alleged contract fixing and bribery charges that lawyers say inflated the value of its assets. The suit was filed on behalf of investors who bought U.S.-traded shares between May 20, 2010 and Nov. 21, 2014. The company's market value dropped to about $60 billion from about $150 billion during the period.

** HOSPIRA INC, Monday close $60.12

U.S. District Judge Gregory Sleet in Delaware ruled that Hospira can launch a generic version of Cubist Pharmaceuticals Inc's leading skin infections drug Cubicin as soon as 2016. (Compiled by Rosmi Shaji in Bengaluru; Editing by Simon Jennings)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below